AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

AN2 Therapeutics, a clinical-stage biopharmaceutical company, is making significant progress in its mission to develop treatments for rare, chronic, and serious infectious diseases with high unmet needs. The company recently announced its participation in the Infectious Disease Society of America (IDSA) IDWeek 2023 Conference, where it will present two oral presentations and three poster presentations.

One of the highlights of AN2 Therapeutics’ presentations is the ongoing enrollment of patients in the Phase 3 part of its pivotal Phase 2/3 clinical trial for the treatment-refractory Mycobacterium avium complex (MAC) lung disease. This trial is evaluating the efficacy of once-daily, oral epetraborole, a novel antibiotic developed by AN2 Therapeutics.

Dr. Paul Eckburg, the Chief Medical Officer of AN2 Therapeutics, expressed excitement about the latest data to be showcased at IDWeek 2023. The data highlights epetraborole’s potent nonclinical activity against MAC isolates and M. abscessus, another difficult-to-treat NTM pathogen. Additionally, the favorable pharmacokinetics of epetraborole in patients with varying degrees of renal impairment and in Japanese subjects with different alcohol dehydrogenase genotypes further support the dosing strategy for patients with treatment-refractory MAC lung disease.

The presentations at IDWeek 2023 include oral presentations and poster presentations that delve into various aspects of epetraborole. The oral presentations will cover topics such as the novel antibiotic’s potential for treating NTM lung disease and melioidosis, as well as its in vitro susceptibility to recent Mycobacterium abscessus isolates. The poster presentations will focus on the safety and pharmacokinetics of epetraborole in adult subjects with varying degrees of renal function, the impact of alcohol dehydrogenase genotype on epetraborole’s pharmacokinetics, and epetraborole’s in vitro activity against recent clinical isolates of MAC from Japan.

AN2 Therapeutics is dedicated to developing treatments for rare, chronic, and serious infectious diseases. Its initial candidate, epetraborole, is being studied as a once-daily, oral treatment with a novel mechanism of action for patients with nontuberculous mycobacteria (NTM) lung disease. This disease is a rare, chronic, and progressive infectious disease caused by mycobacteria, which can lead to irreversible lung damage and be fatal.

The progress made by AN2 Therapeutics in its Phase 2/3 pivotal clinical trial, along with the promising data presented at IDWeek 2023, is expected to provide the basis for regulatory filings for approval in the United States and Japan. The company is enthusiastic about the achievements thus far and remains committed to advancing its mission of developing a novel therapy for patients with treatment-refractory MAC lung disease.

For more information about AN2 Therapeutics and its ongoing research and development efforts, please visit their website at

Leave a comment